Histopathologic effects of a
low molecular weight heparin on bone healing in rats: a promising adjuvant in
dacryocystorhinostomy
Mehmet Numan
Alp 1, Ozdamar Fuad Oken 2, Mustafa Fevzi Sargon 3,
Ahmet Ucaner2
1Department of
Ophthalmology, Numune Training and Research Hospital, Ankara 06100,
Turkey
2Department of Orthopedics and Traumatology, Numune Training
and Research Hospital, Ankara 06100, Turkey
3Department of Anatomy, Faculty of Medicine,
Hacettepe University, Ankara 06100, Turkey
Correspondence to: Mehmet Numan Alp. Turan Gunes Bulvari, 645.
Sokak, Akturk 2 Sitesi, No 24, B Blok, Daire 10, Yukari Dikmen, Ankara 06450, Turkey. mnalp@yahoo.com
Received:
2015-04-15
Accepted: 2015-09-07
Abstract
AIM:
To investigate the effect of short-term prophylactic dose of a low molecular
weight heparin (LMWH) drug on the bone healing process in an animal model
simulating the osteotomy obtained in dacryocystorhinostomy.
METHODS: Forty male Wistar albino rats were divided into 2 groups. Subcutaneous
injections of enoxaparin 1 mg/kg (enoxaparin-treated group) and saline solution
(control group) were performed once daily for 4d, beginning on the first
preoperative day. The osteotomy was created at the femoral diaphysis in all
animals by using a Kirschner wire. Each group was further divided into 2
subgroups depending on the timing of the second operation, 14 or 21d following
initial osteotomy. Patent osteotomy area on the second and the third weeks in
each group were calculated by using a computer software on digital micrographs.
RESULTS: The patent osteotomy areas at the second and the third weeks were
significantly larger in the enoxaparin-treated group than those of the control
group (P<0.001 for each
time-period). In the control group, the patent osteotomy area at the third week
of healing was significantly smaller than that of the second week (P=0.003), whereas there was no
significant difference between these two measurements in the enoxaparin-treated
group (P=0.185).
CONCLUSION: Short-term administration
of enoxaparin resultes in a significant
alteration in bone healing at 14 and 21d after injury. LMWHs can be regarded as promising alternative
adjuvants in dacryocystorhinostomy after being evaluated with further clinical
and animal studies.
KEYWORDS: dacryocystorhinostomy; enoxaparin;
wound healing; low molecular weight
heparin
DOI:10.18240/ijo.2016.06.08
Citation: Alp MN, Oken OF,
Sargon MF, Ucaner A. Histopathologic
effects of a low molecular weight heparin on bone healing in rats: a promising
adjuvant in dacryocystorhinostomy. Int J Ophthalmol 2016;9(6):838-842
INTRODUCTION
Dacryocystorhinostomy (DCR)
is an important treatment in the relief of tearing and could be performed
either through an external or endonasal approach. External DCR has been widely
accepted as the gold standard in the treatment of acquired nasolacrimal duct
obstruction[1]. With the advent of rigid
endoscopes and endoscopic instrumentation, endonasal DCR has become an
alternative method to external DCR, but the success rate of this procedure was
found to be lower than the conventional method[2-3]. The most
frequently reported causes of failure in DCR are obstruction of the common
canalicullus and closure of the osteotomy site due to bone regrowth, fibrosis,
scarring, and granulation tissue[4]. The idea
of inhibiting the causes of failure made the intraoperative application of the
antiproliferative agents to be considered as an adjunctive therapy in DCR.
Mitomycin-C (MMC) has been the most popular antifibrotic agent used in DCR as
well as in pterygium excision and glaucoma surgery with favourable results[5-8]. On the other hand, the presence
of well documented ocular complications related to the adjunctive use of MMC in
pterygium and filtration surgery[9-10] and the current
controversies regarding the optimal dosage and exposure time of MMC[5,7,11] bring considerable limitations
about the routine use of this drug in ophthalmic surgery. Normal wound healing
process may also interfere with the patency of intranasal ostium after the
surgery[8]. Fibrin is accused as a key
product in this process that results in granulation and scar tissue formation
and eventually bone regrowth[12]. Therefore
decreasing or inhibiting fibrin production by pharmacological interruption of
the coagulation cascade seems to be a logical and an alternative method for
preventing the aforementioned causes of failure.
Both heparin and its
derivative, low molecular weight heparin (LMWH), can successfully inhibit
thrombus formation. According to its properties, we feel that LMWHs would
theoretically be as effective as the current antiproliferative agents in the
prevention of fibrosis, scarring, and bone regrowth at the surgical site
following DCR. In this study, we investigated this hypothesis in an animal model
concerning the effect of short-term prophylactic dose of a LMWH on the bone
healing process in rats.
MATERIALS AND METHODS
All experiments
were conducted in accordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research and were approved by Ankara Numune Training and
Research Hospital Ethical Committee and Animal Laboratories of Ankara
University Faculty of Medicine. Forty male Wistar albino rats weighing 280-330
g were maintained under controlled temperature, humidity, and light (12h:12h
artificial light cycle) conditions for at least 10d prior to study. They were
given unlimited access to water and food. On the preoperative day, rats were
arbitrarily assigned to 2 groups of 20 animals each and
were placed in individual cages. Animals in the enoxaparin-treated group were
received 1 mg/kg enoxaparin (Clexane,
Aventis Pharma, France) and those in the control group were treated with the
same volume of normal saline. The subcutaneous injections were administered
once daily to alternate sites of the anterior abdominal wall for 4d beginning
on the first preoperative day.
On the operative day,
anesthesia was induced using intraperitoneal thiopental
at 100 mg/kg body weight. The right femoral bone of each subject was used to
prepare experimental fractures and histological specimens. Each animal was
placed in the left lateral position; hair on the right thigh widely shaved; and
the surgical field was disinfected with povidone iodine solution. Approximately
3 cm of full thickness, longitudinal incision was created to expose muscular
fascia and blunt dissection was performed on the muscles lateral to the femoral
bone. An osteotomy, simulating the one obtained in DCR surgery, was created at
the femoral diaphysis by using a 2.0 mm diameter Kirschner wire (Synthes, Monument, CO, USA). The incision was
sutured back in layers with interrupted 4/0 nylon sutures and the sutures were
removed on the postoperative day 7.
The enoxaparin-treated group and the control group were further divided
into two subgroups each containing randomly chosen 10 animals and reoperated on
the second or the third postoperative weeks to prepare the histological
specimens. Reoperations were performed under thiopental anesthesia and the
animals were sacrificed after complete removal of the previously operated
femoral bones. All of the operations were performed by the same surgeon (Oken OF) who was blind to groups. In both groups, there were no adverse events
including unusual bleeding during or following the operations.
Histological specimens were
prepared including 1 cm of the normal femoral tissue, extending both distally
and proximally to the osteotomy site and the callus tissue. All of the light
and the scanning electron microscopic examinations were performed by the same
doctor (Sargon MF) masked to
which group the specimen was assigned.
For qualitative
analysis of the osteotomy site by scanning electron microscopic examination; the bone samples were fixed in 2.5%
gluteraldehyde for 24h, washed in phosphate buffer (pH 7.4), post-fixed in
1% osmium tetroxide in phosphate buffer (pH 7.4)
for 2h and dehydrated in increasing concentrations of acetone. Following the
dehydration procedure, the samples were air-dried and they were mounted on metal stubs with a double-sided adhesive
band. Then, the specimens were sputtered with a 100 Angstrom thick layer of
gold in a BIO-RAD sputter apparatus (England). All the samples were examined
with a JEOL SEM ASID-10 Scanning Electron Microscope (Jeol Ltd., Tokyo, Japan) at an accelerating voltage of 80 kV.
The patency of osteotomy and
callus formation on the second and the third weeks following the first
operation in the enoxaparin-treated group and the control group were
quantitatively assessed by scanning the photographs taken with a Nikon Optiphot
light microscope (Tokyo, Japan) into high resolution digital images. The patent
osteotomy area was calculated after outlining the callus free area on the
scanned micrographs by using an imaging analysis and software program. In order
to minimize the observer bias, the image analysis was performed by an examiner
masked to which group the micrograph was belonged into.
Statistical
Analysis Statistical analyses were performed by using
SPSS software (version 15.0, SPSS, Inc.). Results are presented as median
(minimum-maximum) values. Mann-Whitney U test was used for evaluation of the statistical significance of
difference between the groups with regard to the use of enoxaparin treatment
and between the subgroups at respective times, as the second and the third
weeks of healing. In each treatment group, one sample t-test was used to compare the changes in the
patent osteotomy area measured on the second and the third weeks of healing to
a reference value of 3.14-mm2 that is the
area of original hole created at the first operation by a 2.0 mm Kirschner
wire. A P-value less than
0.05 was considered statistically significant.
RESULTS
Median values for the patent
osteotomy area measured on the second and the third week of healing for the
enoxaparin-treated and the control groups are shown in Table 1. Patent
osteotomy areas measured both on the second and the third weeks of healing were
statistically significantly larger in the enoxaparin-treated group (Figure 1)
than those of the control group (Figure 2) (Mann-Whitney U test, P<0.001 for each time period). Similarly, in both
the enoxaparin-treated group and the control group, the patent osteotomy areas
measured on the second week of healing were found to be larger than those for
the third week of healing but the difference was statistically significant only
in the control group (Mann-Whitney U
test, P=0.003). In the enoxaparin-treated group and the
control group, the patent osteotomy areas measured on the second and the third
weeks of healing were found to be statistically significantly reduced as
compared to the reference value of 3.14-mm2 (one
sample t-test, P<0.001 for each
time period of each treatment group).
Table 1 The patent osteotomy area of
the groups on the second and the third weeks of healing
Groups |
Second week of healing (mm2) |
Third week of healing (mm2) |
P |
Enoxaparin-treated group |
0.51 (0.39-0.77) |
0.44 (0.30-0.58) |
0.185 |
Control group |
0.26 (0.17-0.38) |
0.14 (0.04-0.27) |
0.003 |
P |
< 0.001 |
< 0.001 |
|
Figure 1 Scanning electron micrograph taken on the third week of healing in the enoxaparin treated group shows a patent osteotomy with smooth edges (arrows) and
minimal callus tissue (asterix) (Original magnification ×200).
Figure 2 Scanning electron micrograph taken on the third week of healing in the control group shows a significantly
occluded osteotomy with ill defined edges (arrow) as a result of extensive
callus formation (asterix) (Original magnification ×200).
The
principle of DCR surgery, either via
an external skin incision or via
endonasal approach, is similar to glaucoma surgery. It is to achieve an incomplete healing after DCR
surgery to enhance lacrimal outflow into the nose through a patent osteotomy
created on the lacrimal bone. Success rates of this procedure have been
reported to be over 90% in most of the previous studies[13].
Although it has been generally accepted that an osteotomy size of 15 to 20 mm
in diameter is enough to be successful in external DCR, Linberg et al[14]
showed that the diameter of the healed intranasal ostium was decreased to 1.8
mm, that was only 10% size of the initial surgical ostium, in the postoperative
period with excellent functional results[15]. This
finding made endoscopic DCR as an alternative method with less disfavors as
compared to external DCR. However, the success rate of endoscopic DCR was found
to be lower than external DCR[2].
Obstruction of the common canalicullus and closure of the rhinostomy site due
to the consequences of normal wound healing pathways, such as bone regrowth,
fibrosis, scarring, and granulation tissue have been reported as the most
common causes of DCR failure[3-4,13].
Serial biological events leading to tissue repair occur following a surgical
injury to the tissue. Replacement processes take place in the initial phase of
repair and involve inflammation and coagulation cascades that ultimately lead
to scar tissue formation. On the other hand, regeneration processes result in a
variable degree of restoration of the original tissue structure and formation
of the scar tissue depending on the regeneration capacity of the injured
tissue. Inflammation and scar tissue formation can be subsided by taking some
meticulous precautions, such as preoperative evaluation and management of
intranasal abnormalities, prevention of thermal damage associated with the
excessive use of lasers and drills, or avoiding unnecessary trauma through
gentle handling of tissue during surgery. However, other causes associated with
the normal wound healing may also interfere with the success of DCR. According
to Lama and Fechtner[16], normal
wound healing cascade can theoretically be modulated at several stages by using
different pharmacological agents interfering with particular factors involved
in the pathway. They simply classified these agents into four groups with
regard to the main phases of repair: coagulative, inflammatory, proliferative,
and post-proliferative remodeling. Many authors, for example, recommend the
intraoperative application of MMC to the surgical anastamosis as an antiproliferative
agent in this manner[7-8]. MMC is an
alkylating agent that inhibits fibroblast proliferation at the rhinostomy site
with favourable outcomes. However, its use is advocated especially in the
setting of a failed DCR because of its potential for significant ocular and
intranasal complications[9]. Therefore, there have been some efforts to
find a substitute for MMC in prevention of surgical failure.
Pharmacologically interrupting the coagulation cascade
at an
earlier step could theoretically
modulate the wound healing response and prevent the closure of surgical
osteotomy. Zilelioglu et al[8] reported that the decrease in the
size of the healed intranasal ostium after surgery was the result of a normal
wound healing response. Wound healing may be considered as one of the
activities of hemostasis, which is initiated by direct tissue injury and blood
vessel disruption as a result of surgical manipulation. Fibrin is the end
product of the coagulation process and is formed by conversion of fibrinogen to
fibrin by thrombin. Fibrin is responsible for a series of histochemical
reactions, such as platelet aggregation, proliferation and synthesis of
extracellular matrix, that eventually result in granulation and scar tissue
formation[12].
Both heparin and its derivative,
LMWH, can successfully inhibit thrombus formation. Heparin has some limitations
based on its pharmacokinetic, biophysical, and biological properties not shared
by LMWHs[17]. LMWH preparations are
produced by chemical or enzymatic depolymerization of native heparin and are
considered to be more convenient in the prophylactic inhibition of fibrin
formation. The studies concerning the efficacy and safety of LMWHs have shown that
LMWHs equally prevent deep venous thrombosis and pulmonary embolism and result
in significantly lesser bleeding complications when compared to unfractionated
heparin and warfarin[18]. LMWHs do not ineract with
platelet function and do not modify bleeding time, thus, requiring less intense
laboratory monitoring. Although LMWHs are mainly used for thromboprophylaxis in
orthopedic surgery, they have been also found to be safe and effective in the
prevention of ocular scarring and neovascularization disorders by reduction of
cell-mediated contraction and cellular proliferation[18-19].
The subject of the current
study is mainly based on the clinical and experimental observations elucidating
the side effects of LMWHs on bone healing process. Long-term uses of heparin
and LMWHs have been shown to carry a risk of osteoporosis as a biological
limitation[20-22]. Standard heparin has
been reported to decrease bone formation and increase bone resorption[22]. Although, there are a number of
studies reporting a similar or a lesser effect of LMWHs on the skeletal system,
the exact mechanism of LMWHs on bone healing when used with a standard dosage
for thromboprophylaxis have not been fully understood[20-23].
In an unstabilized rabbit rib fracture model, Street et al[24] has
suggested that a short-term administration of LMWH thromboprophylaxis would
delay bone healing by two distinct mechanisms, either by disrupting the
formation of osteoprogenitor units or by increasing bleeding tendency that
would cause interfragmentary hematoma collection. Although it is generally
accepted that the fracture site hematoma plays a beneficial role in fracture
healing, they reported that an increased amount of fracture site hematoma
comprises high potassium concentration that is cytotoxic to endothelial cells
and osteoblasts and may display negative effects on bone formation during
fracture healing that could be accepted as a welcome effect for DCR. As a
consequence of these observations related with the short-term use of LMWHs in
clinical practice of orthopedic surgery, this study was initiated to
investigate the potentially beneficial effect of short-term prophylactic dose
of a LMWH on the bone healing process in an animal model, in which a Kirschner
wire was used to create an osteotomy with a similar diameter to the healed
intranasal ostium obtained after DCR with sufficient functional results[14-15].
The present study revealed
that, although, the patent osteotomy area decreased after two weeks and three
weeks in all of the animals treated with or without enoxaparin, the decrease
was statistically significant only in the control group. Moreover,
the patent osteotomy areas measured both on the second and the third weeks of
healing remained significantly larger in enoxaparin treated animals
when compared to those of the controls. This observation seems to support our hypothesis
that an exposure to enoxaparin may affect early bone healing and may alter the
closure of osteotomy site in the early postoperative period following DCR. On
the other hand, we feel that there are some limitations to the routine use of
LMWHs in DCR as an adjunctive drug. The main limitation is probably an
increased tendency for intraoperative and postoperative bleeding related with
DCR in patients receiving LMWH. It has been suggested that these drugs are
discontinued if possible upon consultation with the patient’s primary care
physician. On the other hand, there are reports suggesting that endoscopic DCR
is a safe and efficient treatment for relief of distal nasolacrimal duct
obstruction in anti-coagulated patients as compared to patients without
anti-coagulation therapy and does not require discontinuing their
anti-coagulant therapy, including warfarin and coumadin[25-26]. We suggest that
choosing the most effective and the safest administration route (systemic vs topical), dosage, and exposure time
of LMWH are the other issues related with the adjunctive use of these drugs in
DCR surgery remain to be investigated with further studies.
The current study we presented
is a preliminary animal study and shows that short-term administration of a low
dose of enoxaparin resulted in a significant alteration in bone healing with
less callus formation at 14 and 21d after injury. Our results suggest that
LMWHs could be regarded as promising alternative adjuvants in DCR surgery. We
also believe that additional clinical and animal studies regarding the aspects
so far mentioned are required to assert the routine use of LMWHs in DCR surgery
and to compare these drugs with currently used antiproliferative agents.
ACKNOWLEDGEMENTS
Conflicts of Interest: Alp MN, None; Oken OF, None; Sargon MF, None; Ucaner A,
None.
REFERENCES
1 Olver J. Surgery of the lacrimal system. In: Spaeth GL, Danesh-Meyer
HV, Goldberg I, Kampik A, editors. Ophthalmic surgery: Principles and practice.
Edinburgh: Elsevier; 2012: 399-341.
2 Anijeet D, Dolan L, Macewen CJ.
Endonasal versus external dacryocystorhinostomy for nasolacrimal duct
obstruction. Cochrane Database Syst Rev 2011;(1):CD007097. [CrossRef]
3 Zaidi GH, Symanski S, Olver JM.
A clinical trial of endoscopic vs external dacryocystorhinostomy for partial
nasolacrimal duct obstruction. Eye (Lond)
2011;25(9):1219-1224. [CrossRef]
[PubMed] [PMC free article]
4 Balikoglu-Yilmaz M, Yilmaz T,
Taskin U, Taskapili M, Akcay M, Oktay MF, Eren S. Prospective comparison of 3
dacryocystorhinostomy surgeries: external versus endoscopic versus
transcanalicular multidiode laser. Ophthal
Plast Reconstr Surg 2015;31(1):13-18. [CrossRef] [PubMed]
5 Kaufman SC, Jacobs DS, Lee WB,
Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for
pterygium: a report by the American Academy of Ophthalmology. Ophthalmology 2013;120(1):201-208. [CrossRef] [PubMed]
6 Yarangumeli A, Koz OG, Alp MN,
Elhan AH, Kural G. Viscocanalostomy with mitomycin C: a preliminary study. Eur J Ophthalmol 2005;15(2):202-208. [PubMed]
7 Xue K, Mellington FE, Norris JH.
Meta-analysis of the adjunctive use of mitomycin C in primary and revision,
external and endonasal dacryocystorhinostomy. Orbit 2014;33(4):239-244.
[CrossRef] [PubMed]
8 Zilelioglu, Ugurbas SH, Anadolu
Y, Akiner M, Aktürk T. Adjunctive use of mitomycin C on endoscopic lacrimal
surgery. Br J Ophthalmol
1998;82(1):63-66. [CrossRef]
[PubMed]
9 Lindquist TP, Lee WB. Mitomycin
C-associated scleral stromalysis after pterygium surgery. Cornea 2015;34(4):398-401. [CrossRef] [PubMed]
10 Katz GJ, Higginbotham EJ,
Lichter PR, Skuta GL, Musch DC, Bergstrom TJ, Johnson AT. Mitomycin C versus 5
fluorouracil in high risk glaucoma filtering surgery. Ophthalmology 1995;102(9):1263-1269. [CrossRef]
11 Megevand GS, Salmon JF, Scholts
RP, Murray AD. The effect of reducing the exposure time of mitomycin C in
glaucoma filtering surgery. Ophthalmology
1995;102(1):84-90. [CrossRef]
12 Midwood KS, Williams LV,
Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol
2004;36(6):1031-1037. [CrossRef]
[PubMed]
13 Huang J, Malek J, Chin D,
Snidvongs K, Wilcsek G, Tumuluri K, Sacks R, Harvey RJ. Systematic review and
meta-analysis on outcomes for endoscopic versus external dacryocystorhinostomy.
Orbit 2014;33(2):81-90. [CrossRef] [PubMed]
14 Linberg JV, Anderson RL,
Bumsted RM, Barreras R. Study of intranasal ostium external
dacryocystorhinostomy. Arch Ophthalmol
1982;100(11):1758-1762. [CrossRef]
15 Bumsted RM, Linberg JV,
Anderson RL, Barreras R. External dacryocystorhinostomy. a prospective study
comparing the size of the operative and healed ostium. Arch Otolaryngol 1982;108(7):407-410. [CrossRef]
16 Lama PJ, Fechtner RD.
Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48(3):314-346. [CrossRef]
17 Hirsh J, Warkentin TE,
Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen
JE. Heparin and low molecular weight heparin: mechanisms of action,
pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001;119(1 Suppl): 64S-94S. [CrossRef] [PubMed]
18 Palmer AJ, Koppenhagen K,
Kirchhof B, Weber U, Bergemann R. Efficacy and safety of low molecular weight heparin,
unfractionated heparin, and warfarin for thromboembolism prophylaxis in
orthopedic surgery: a meta-analysis of randomized clinical trials. Haemostasis 1997;27(2):75-84. [PubMed]
19 Aydin E, Kivilcim M, Peyman GA,
Esfahani MR, Kazi AA Sanders DR. Inhibition of experimental angiogenesis of
cornea by various doses of doxycycline and combination of triamcinolone
acetonide with low molecular weight heparin and doxycycline. Cornea 2008;27(4):446-453. [CrossRef] [PubMed]
20 Lefkou E, Khamashta M, Hampson
G, Hunt BJ. Review: Low-molecular-weight heparin-induced osteoporosis and
osteoporotic fractures: a myth or an existing entity? Lupus 2010;19(1):3-12. [CrossRef] [PubMed]
21 Muir JM, Hirsh J, Weitz JI,
Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the
effects of heparin and low molecular weight heparin on cancellous bone in rats.
Blood 1997;89(9):3236-3242. [PubMed]
22 Shaughnessy SG, Young E,
Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin
on calcium loss from fetal rat calvaria. Blood
1995;86(4):1368-1373. [PubMed]
23 Matzsch T, Bergqvist D, Hedner
U, Nilsson B, Ostergaard P. Effects of low molecular weight heparin and
unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 1990;63(3):505-509. [PubMed]
24 Street JT, McGrath M, O’Regan
K, Wakai A, McGuinness A, Redmond HP. Thromboprophylaxis using a low molecular
weight heparin delays fracture repair. Clin
Orthop Relat Res 2000;(381):278-289. [CrossRef] [PubMed]
25 Smithard A, Wynne D, Bingham
BJ, Jones NS. Endonasal laser dacryocystorhinostomy: its role in anticoagulated
patients. Laryngoscope
2003;113(6):1034-1036. [CrossRef] [PubMed]
26 Smith W, Merkonidis C, Draper M, Yung
M. Endoscopic dacryocystorhinostomy in warfarinized patients. Am J Ophthalmol 2006;27(5):327-329. [CrossRef]
[Top]